Metformin reduces asymmetric dimethylarginine and prevents hypertension in spontaneously hypertensive rats

Translational Research

Volumn 164, Issue 6, 2014, Pages 452-459

  Tsai, Chih Min ^a,b   Kuo, Hsuan Chang ^a,b   Hsu, Chien Ning ^a,c   Huang, Li Tung ^a,b   Tain, You Lin ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^c KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIMETHYLARGININASE; METFORMIN; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; PROTEIN ARGININE METHYLTRANSFERASE; AMIDASE; ARGININE; N,N-DIMETHYLARGININE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; CONTROLLED STUDY; DIABETIC PATIENT; HYPERTENSION; KIDNEY; MALE; NONHUMAN; PLASMA; PREHYPERTENSION; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; ANALOGS AND DERIVATIVES; ANIMAL; BIOSYNTHESIS; BLOOD; BODY WEIGHT; DRUG EFFECTS; ENZYMOLOGY; LUNG; METABOLISM; PATHOPHYSIOLOGY; WISTAR KYOTO RAT;

AMIDOHYDROLASES; ANIMALS; ARGININE; BLOOD PRESSURE; BODY WEIGHT; HYPERTENSION; KIDNEY; LUNG; MALE; METFORMIN; NITRIC OXIDE; RATS, INBRED SHR; RATS, INBRED WKY;

EID: 84910662124     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2014.07.005     Document Type: Article

References (32)

1. C.S. Wilcox Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension? Am J Physiol Regul Integr Comp Physiol 289 2005 R913 R935
2. N.D. Vaziri Roles of oxidative stress and antioxidant therapy in chronic kidney disease and hypertension Curr Opin Nephrol Hypertens 13 2004 93 99
3. K. Sydow, and T. Münzel ADMA and oxidative stress Atheroscler Suppl 4 2003 41 51
4. H. Matsuoka, S. Itoh, and M. Kimoto Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension Hypertension 29 1997 242 247
5. R.H. Böger Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the L-arginine paradox and acts as a novel cardiovascular risk factor J Nutr 134 2004 S2842 S2847
6. T. Teerlink, Z. Luo, F. Palm, and C.S. Wilcox Cellular ADMA: regulation and action Pharmacol Res 60 2009 448 460
7. Y.L. Tain, and L.T. Huang Asymmetric dimethylarginine: clinical applications in pediatric medicine J Formos Med Assoc 110 2011 70 77
8. C.N. Hsu, L.T. Huang, Y.T. Lau, C.Y. Lin, and Y.L. Tain The combined ratios of L-arginine and asymmetric and symmetric dimethylarginine as biomarkers in spontaneously hypertensive rats Transl Res 159 2012 90 98
9. Y.L. Tain, L.T. Huang, I.C. Lin, Y.T. Lau, and C.Y. Lin Melatonin prevents hypertension and increased asymmetric dimethylarginine in young spontaneous hypertensive rats J Pineal Res 49 2010 390 398
10. Y.L. Tain, C.N. Hsu, L.T. Huang, and Y.T. Lau Apocynin attenuates oxidative stress and hypertension in young spontaneously hypertensive rats independent of ADMA/NO pathway Free Radic Res 46 2012 68 76
11. S.J. Chien, K.M. Lin, and H.C. Kuo Two different approaches to restore renal nitric oxide and prevent hypertension in young spontaneously hypertensive rats: L-citrulline and nitrate Transl Res 163 2014 43 52
12. B. Viollet, B. Guigas, N. Sanz Garcia, J. Leclerc, M. Foretz, and F. Andreelli Cellular and molecular mechanisms of metformin: an overview Clin Sci (Lond) 122 2012 253 270
13. P. Andújar-Plata, X. Pi-Sunyer, and B. Laferrère Metformin effects revisited Diabetes Res Clin Pract 95 2012 1 9
14. V. De Leo, M.C. Musacchio, P. Piomboni, A. Di Sabatino, and G. Morgante The administration of metformin during pregnancy reduces polycystic ovary syndrome related gestational complications Eur J Obstet Gynecol Reprod Biol 157 2011 63 66
15. H. He, Z. Zhao, and J. Chen Metformin-based treatment for obesity-related hypertension: a randomized, double-blind, placebo-controlled trial J Hypertens 30 2012 1430 1439
16. S. Verma, S. Bhanot, and J.H. McNeill Metformin decreases plasma insulin levels and systolic blood pressure in spontaneously hypertensive rats Am J Physiol 267 1994 H1250 H1253
17. R.C. Bhalla, K.F. Toth, E. Tan, R.A. Bhatty, E. Mathias, and R.V. Sharma Vascular effects of metformin. Possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat Am J Hypertens 9 1996 570 576
18. M.S. Muntzel, I. Hamidou, and S. Barrett Metformin attenuates salt-induced hypertension in spontaneously hypertensive rats Hypertension 33 1999 1135 1140
19. W.H. Bestermann Jr. The ADMA-metformin hypothesis: linking the cardiovascular consequences of the metabolic syndrome and type 2 diabetes Cardiorenal Med 1 2011 211 219
20. K. Sydow, C.E. Mondon, and J.P. Cooke Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA Vasc Med 10 2005 S35 S43
21. T. Asagami, F. Abbasi, and M. Stuelinger Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes Metabolism 51 2002 843 846
22. Y.L. Tain, and C. Baylis Determination of dimethylarginine dimethylaminohydrolase activity in the kidney Kidney Int 72 2007 886 889
23. Y.L. Tain, W.C. Lee, and C.N. Hsu Asymmetric dimethylarginine is associated with developmental programming of adult kidney disease and hypertension in offspring of streptozotocin-treated mothers PLoS ONE 8 2013 e55420
24. P. Bulau, D. Zakrzewicz, and K. Kitowska Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA Am J Physiol Lung Cell Mol Physiol 292 2007 L18 L24
25. D. Detaille, B. Guigas, X. Leverve, N. Wiernsperger, and P. Devos Obligatory role of membrane events in the regulatory effect of metformin on the respiratory chain function Biochem Pharmacol 63 2002 1259 1272
26. J. Strobel, M. Mieth, and B. Endress Interaction of the cardiovascular risk marker asymmetric dimethylarginine (ADMA) with the human cationic amino acid transporter 1 (CAT1) J Mol Cell Cardiol 53 2012 392 400
27. S.M. Bode-Boger, F. Scalera, and L.J. Ignarro The L-arginine paradox: importance of the L-arginine/asymmetrical dimethylarginine ratio Pharmacol Ther 114 2007 295 306
28. M. Iwase, K. Ichikawa, and K. Tashiro Effects of monosodium glutamate-induced obesity in spontaneously hypertensive rats vs. Wistar Kyoto rats: serum leptin and blood flow to brown adipose tissue Hypertens Res 23 2000 503 510
29. R.J. Ford, S.R. Teschke, E.B. Reid, K.K. Durham, J.T. Kroetsch, and J.W. Rush AMP-activated protein kinase activator AICAR acutely lowers blood pressure and relaxes isolated resistance arteries of hypertensive rats J Hypertens 30 2012 725 733
30. J.Y. Sung, and H.C. Choi Metformin-induced AMP-activated protein kinase activation regulates phenylephrine-mediated contraction of rat aorta Biochem Biophys Res Commun 421 2012 599 604
31. A. Rocha, M. Almeida, J. Santos, and A. Carvalho Metformin in patients with chronic kidney disease: strengths and weaknesses J Nephrol 26 2013 55 60
32. J.L. Sartoretto, G.A. Melo, and M.H. Carvalho Metformin treatment restores the altered microvascular reactivity in neonatal streptozotocin-induced diabetic rats increasing NOS activity, but not NOS expression Life Sci 77 2005 2676 2689